Intra-Cellular Therapies Shares Down 15.7% In Sympathy With Alkermes After FDA Refuses To Review ALKS-5461; Earlier, Stat News' Adam F Tweeted: 'Anyone confident in $ITCI now? I wouldn't be.'
Hal Lindon